Detalhe da pesquisa
1.
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.
Nature
; 595(7868): 572-577, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34044428
2.
Potential for Maternally Administered Vaccine for Infant Group B Streptococcus.
N Engl J Med
; 389(3): 215-227, 2023 Jul 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37467497
3.
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses.
Nature
; 586(7830): 594-599, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32998157
4.
Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine.
N Engl J Med
; 386(20): 1910-1921, 2022 05 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35320659
5.
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
N Engl J Med
; 386(1): 35-46, 2022 01 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34752019
6.
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.
N Engl J Med
; 385(3): 239-250, 2021 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34043894
7.
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months.
N Engl J Med
; 385(19): 1761-1773, 2021 11 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34525277
8.
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
N Engl J Med
; 383(27): 2603-2615, 2020 12 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-33301246
9.
Publisher Correction: COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses.
Nature
; 590(7844): E17, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33469214
10.
A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults.
N Engl J Med
; 377(24): 2349-2362, 2017 12 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-29236639
11.
A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years.
BMC Infect Dis
; 20(1): 426, 2020 Jun 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32552685
12.
A phase 3, randomized, controlled, open-label study to evaluate the persistence up to 5 years of 1 or 2 doses of meningococcal conjugate vaccine MenACWY-TT given with or without 13-valent pneumococcal conjugate vaccine in 12-14-month-old children.
Vaccine
; 41(5): 1153-1160, 2023 01 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36621408
13.
Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial.
Lancet Infect Dis
; 23(12): 1370-1382, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37579773
14.
Safety and immunogenicity of a primary series and booster dose of the meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp) in healthy children aged 1-9 years: two phase 2 randomised, controlled, observer-blinded studies.
Lancet Infect Dis
; 23(1): 103-116, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36087588
15.
A phase 3 study to assess the immunogenicity, safety, and tolerability of MenB-FHbp administered as a 2-dose schedule in adolescents and young adults.
Vaccine
; 40(2): 351-358, 2022 01 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-34961633
16.
Safety data from the MenB-FHbp clinical development program in healthy individuals aged 10 years and older.
Vaccine
; 40(12): 1872-1878, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35164991
17.
Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial.
Vaccine
; 40(10): 1483-1492, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35131133
18.
Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months.
Vaccine
; 39(32): 4545-4554, 2021 07 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34215452
19.
Sex, Age, and Race Effects on Immunogenicity of MenB-FHbp, A Bivalent Meningococcal B Vaccine: Pooled Evaluation of Clinical Trial Data.
Infect Dis Ther
; 9(3): 625-639, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32681472
20.
Efficacy and safety of a booster dose of the meningococcal A, C, W, Y-tetanus toxoid conjugate vaccine administered 10 years after primary vaccination and long-term persistence of tetanus toxoid conjugate or polysaccharide vaccine.
Hum Vaccin Immunother
; 16(6): 1272-1279, 2020 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32401600